Browsing by Author "Kutlay, S"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak
    Yalcinkaya, EY; Karadag Saygi, E; Özyemisci Taskiran, O; Çapan, N; Kutlay, S; Sonel Tur, B; Özlem, EL; Ünlu Akyüz, E; Tekin, S; Ofluoglu, D; Zinnuroglu, M; Akpinar, P; Özekli Misirlioglu, T; Hüner, B; Nur, H; Çaglar, S; Sezgin, M; Tikiz, C; Önes, K; Içagasioglu, A; Aydin, R
    Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT) injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared and adapted to the Delphi technique by PMR specialists. Then they were asked to the physicians experienced in BoNT injections (PMR specialist, pediatric orthopedists, and pediatric neurologists) or COVID-19 (pediatric infectious disease, adult infectious disease). In conclusion, the experts agree that conservative management approaches for spasticity may be the initial steps before BoNT injections. BoNT injections can be administered to children with CP with appropriate indications and with necessary precautions during the pandemic.
  • No Thumbnail Available
    Item
    Prevalence of Rheumatoid Arthritis and Spondyloarthritis in Turkey: A Nationwide Study
    Tuncer, T; Gilgil, E; Kaçar, C; Kurtais, Y; Kutlay, S; Bütün, B; Yalçin, P; Akarirmak, Ü; Altan, L; Ardiç, F; Ardiçoglu, Ö; Altay, Z; Cantürk, F; Cerrahoglu, L; Çevik, R; Demir, H; Durmaz, B; Dursun, N; Duruöz, T; Erdogan, C; Evcik, D; Gürsoy, S; Hizmetli, S; Kaptanoglu, E; Kayhan, Ö; Kirnap, M; Kokino, S; Kozanoglu, E; Kuran, B; Nas, K; Öncel, S; Sindel, D; Orkun, S; Sarpel, T; Savas, S; Sendur, OF; Senel, K; Ugurlu, H; Uzunca, K; Tekeoglu, I; Guillemin, F
    Objectives: This study aims to estimate the prevalence of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in Turkey using the same telephone questionnaire developed for screening RA and SpA in France and used in Serbia and Lithuania. Material and methods: The study was performed in two steps. In step I, the French questionnaire was translated into Turkish and validated through a group of 200 patients (80 males, 120 females; mean age 44.0 +/- 13.1 years; range, 19 to 75 years) followed up at the rheumatology departments of University Hospitals in Antalya and Ankara. In step II, the validated Turkish questionnaire was administered face-to-face to randomly selected 4,012 subjects (1,670 males, 2,342 females; mean age 41.5 +/- 16.8 years; range, 16 to 97 years) by trained general practitioners across the country, in 25 provinces for case detection. The subjects who were suspected of having RA or SpA in accordance with the questionnaire were invited to the nearest university hospital for rheumatologic examination in order to confirm the diagnosis. Results: In step II, a total of 25 subjects (2 males, 23 females) were diagnosed as RA. The standardized RA prevalence for the general population of Turkey was calculated as 0.56% (95% confidence interval [CI]; 0.33-0.79), 0.10% (95% CI; -0.05-0.25) for males and 0.89% (95% CI; 0.51-1.27) for females. A total of 18 subjects (3 males, 15 females) were diagnosed as SpA. The standardized SpA prevalence for the general population of Turkey was 0.46% (95% CI; 0.25-0.67), 0.17% (95% CI; -0.03-0.37) for males and 0.65% (95% CI; 0.32-0.98) for females. The prevalence of RA was highest in the Northern region (2.00%) and the prevalence of SpA was highest in the Central region (1.49%). Conclusion: The prevalences of RA and SpA in Turkey are close to each other and there are significant inter-regional variations in prevalences of both RA and SpA.